Skip to main content

Table 1 Summary of patient and tumor characteristics

From: Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

  Tamoxifen cohort 1 Untreated   Low MKS High MKS   Tamoxifen
High ERS Low ERS High ERS Low ERS   cohort 2
Characteristic N % N % P a N % N % N % N % P b N %
Patients 683   559    373   248   248   373    282  
Age, years                 
   ≤50 43 6.3 240 42.9 <0.0001 82 22.0 47 19.0 57 23.0 96 25.7 0.247 8 2.8
   >50 498 72.9 306 54.8 240 64.3 172 69.3 160 64.5 233 62.5 176 62.4
   Unknown 142 20.8 13 2.3 51 13.7 29 11.7 31 12.5 44 11.8 98 34.8
Tumor (T) stage                 
   T1 214 31.3 199 35.6 <0.0001 145 38.9 102 41.1 74 29.8 92 24.7 0.003 109 38.7
   T2/T3 293 42.9 140 25.0 126 33.8 82 33.1 84 33.9 141 37.8 168 59.5
   Unknown 176 25.8 220 39.4 102 27.3 64 25.8 90 36.3 140 37.5 5 1.8
Nodal status                 
   Negative 403 59.0 559 100.0 <0.0001 295 79.1 192 77.4 191 77.0 284 76.1 0.962 147 52.1
   Positive 258 37.8 0 0.0 76 20.4 50 20.2 52 21.0 80 21.5 111 39.4
   Unknown 22 3.2 0 0.0 2 0.5 6 2.4 5 2.0 9 2.4 24 8.5
Grade                 
   1 108 15.8 66 11.8 0.0002 86 23.1 54 21.8 18 7.3 16 4.3 <0.0001 26 9.2
   2 258 37.8 242 43.3 159 42.6 105 42.3 108 43.5 128 34.3 114 40.4
   3 111 16.3 152 27.2 29 7.8 32 12.9 63 25.4 139 37.3 44 15.6
   Unknown 206 30.2 99 17.7 99 26.5 57 23.0 59 23.8 90 24.1 98 34.8
HER2 by gene c                 
   HER2-positive 27 4.0 44 7.9 0.169 1 0.3 8 3.2 7 2.8 55 14.8 <0.0001 - 0.0
   HER2-negative 647 94.7 515 92.1 371 99.4 239 96.4 239 96.4 313 83.9 - 0.0
   Unknown 9 1.3 0 0.0 1 0.3 1 0.4 2 0.8 5 1.3 282 100.0
Distant events, time cohorts                 
   0 to 10 yrs 137   144   - 42   37   65   137   - 64  
   0 to 2.5 yrs 46   55   8   9   17   67   26  
   2.5 to 5 yrs 48   55   19   10   21   53   20  
   >5 yrs 43   34   15   19   26   17   18  
   Unknown 10   6    2   6   3   5    -  
  1. aOnly patients with known clinical information were considered for comparison between tamoxifen-treated (cohort 1) and untreated patients. bOnly patients with known clinical information were considered for comparison among the four molecular groups. P-values in boldface were statistically significant at P <0.05. These molecular groups referred to the tamoxifen-treated (cohort 1) and untreated patients. cHER2 status was defined according to Haibe-Kains et al. [21]. N, number of patients; MKS, mitotic kinase score; ERS, estrogen-related score; HER2: human epidermal growth factor receptor 2.